78th Apollo clinic launched in Uppal

IMT News Desk
IMT News Desk
· 2 min read

Apollo Health and Lifestyle Ltd. (AHLL), has launched its 78th multi-speciality clinic facility, at Uppal in Hyderabad. With this launch the company is inching closer to its goal of having 100 clinics across India by 2018.

Sangita Reddy, chairperson & managing director, Apollo Health and Lifestyle Limited said, “With the launch of the new multi-specialty clinic we have broadened our reach this time around in the growing suburb of Uppal. Apollo Clinics are family care centres which cater to all the medical needs of all family members. The launch of the new Apollo Clinic at Uppal reflects our commitment to providing superior quality health care services, world class treatment facilities and expert consultants to address the day-to-day healthcare needs of people all over the country.”

The company had recently said that it would invest Rs 500 crore in the next five years to expand its core businesses across the country. The subsidiary of Apollo Hospitals Enterprise has five primary care formats; Apollo Clinics, Apollo Sugar, Apollo Diagnostics, Apollo White and Apollo Dialysis.

Last December, AHLL has raised around Rs 450 crore from the International Finance Corporation (IFC) by selling 29 per cent stake in the company.

At present, AHLL has 72 Apollo White dental hospitals, 42 Apollo Diagnostics, 12 Apollo Spectra surgical hospitals and six Apollo Dialysis centres in the country.

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk